Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG2315 E-COMBI: Local steroid injection vs injection plus oral steroid to prevent esophageal stricture after ESD
jRCTs031240545Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of prednisolone and triamcinolone acetonide in esophageal cancer and Esophageal stricture (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Stricture-free survival. Started Dec 2024; status: recruiting.
02
Drugs
prednisolonetriamcinolone acetonide
03
Conditions
esophageal cancerEsophageal stricture
Beyond the preview
Go deeper on jRCTs031240545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240545.